Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 2/20 | 0.41 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL46482 | 0.89 | FYN (0.34) | GSK3BHDAC4HDAC1HDAC6FYN | |
| SCHEMBL43893 | 0.89 | GSK3B (0.44) | GSK3BHDAC4HDAC6GAA | |
| SCHEMBL43831 | 0.89 | GAA (0.43) | GSK3BGAA | |
| SCHEMBL44764 | 0.88 | GAA (0.44) | GSK3BGAA | |
| SCHEMBL45068 | 0.86 | HPGD (0.38) | HDAC4HDAC1HDAC6FYNCAMK2D | |
| SCHEMBL43913 | 0.85 | GAA (0.43) | GSK3BGAA | |
| SCHEMBL44476 | 0.83 | GAA (0.37) | HDAC4FYNGAA | |
| SCHEMBL44251 | 0.83 | GSK3B (0.48) | GSK3B | |
| SCHEMBL43987 | 0.81 | RAB9A (0.55) | — | |
| SCHEMBL994121 | 0.81 | LMNA (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2214669-B1 | CYTOKINE INHIBITORS | HUTCHISON MEDIPHARMA ENTPR LTD (BS) | 2015-04-01 | — | — | EP | claimed |
| US-7868001-B2 | Cytokine inhibitors | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2011-01-11 | — | — | US | claimed |
| US-20090118292-A1 | such as 2-(3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)imidazo[1,2-b]pyridazine, used for decreasing the levels of tumor necrosis factors or interleukines; treatment of inflammation, autoimmune diseases, diabetes, atherosclerosis and cancer | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (CN) | 2009-05-07 | — | — | US | claimed |
| EP-2214669-B1 | CYTOKINE INHIBITORS | HUTCHISON MEDIPHARMA ENTPR LTD (BS) | 2015-04-01 | — | — | EP | disclosed |
| EP-2214669-B1 | CYTOKINE INHIBITORS | HUTCHISON MEDIPHARMA ENTPR LTD (BS) | 2015-04-01 | — | — | EP | disclosed |
| WO-2011137587-A1 | CYTOKINE INHIBITORS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2011-11-10 | — | — | WO | disclosed |
| US-7868001-B2 | Cytokine inhibitors | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2011-01-11 | — | — | US | disclosed |
| US-7868001-B2 | Cytokine inhibitors | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2011-01-11 | — | — | US | disclosed |
| US-7868001-B2 | Cytokine inhibitors | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2011-01-11 | — | — | US | disclosed |
| EP-2214669-A1 | CYTOKINE INHIBITORS | Hutchison Medipharma Enterprises Limited (BS) | 2010-08-11 | — | — | EP | disclosed |
| US-20090118292-A1 | such as 2-(3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)imidazo[1,2-b]pyridazine, used for decreasing the levels of tumor necrosis factors or interleukines; treatment of inflammation, autoimmune diseases, diabetes, atherosclerosis and cancer | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (CN) | 2009-05-07 | — | — | US | disclosed |
| US-20090118292-A1 | such as 2-(3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)imidazo[1,2-b]pyridazine, used for decreasing the levels of tumor necrosis factors or interleukines; treatment of inflammation, autoimmune diseases, diabetes, atherosclerosis and cancer | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (CN) | 2009-05-07 | — | — | US | disclosed |
| US-20090118292-A1 | such as 2-(3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)imidazo[1,2-b]pyridazine, used for decreasing the levels of tumor necrosis factors or interleukines; treatment of inflammation, autoimmune diseases, diabetes, atherosclerosis and cancer | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (CN) | 2009-05-07 | — | — | US | disclosed |
| WO-2009059162-A1 | CYTOKINE INHIBITORS | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009059162-A1 | CYTOKINE INHIBITORS | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118292-A1 | such as 2-(3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)imidazo[1,2-b]pyridazine, used for decreasing the levels of tumor necrosis factors or interleukines; treatment of inflammation, autoimmune diseases, diabetes, atherosclerosis and cancer | IL1B, IL1A, IL17A | GSK3B 1103/4885HDAC4 3373/4885HDAC1 1378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.